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One-pot total chemical synthesis of human
a-synuclein†
Bruno Fauvet,za Sara M. Butterfield,za Jonas Fuks,a Ashraf Brikb and
Hilal A. Lashuel*a
Post-translational modifications (PTMs) regulate key aspects of the physio-
logical and pathogenic properties of Parkinson’s disease-associated pre-
synaptic protein a-synuclein. We herein describe a one-pot total chemical
synthesis that should enable site-specific introduction of single or multiple
PTMs or small molecule probes essentially at any site within the protein.
The misfolding and aggregation of the 140-residue neuronal protein
a-synuclein (a-syn) play central roles in the pathogenesis of Parkin-
son’s disease (PD).1 Histologically, PD is defined post-mortem by the
presence of intracellular proteinaceous inclusions known as Lewy
bodies (LBs), composed mainly of insoluble a-syn amyloid fibrils.
Several post-translational modifications (PTMs) have been identified
in a-syn within LBs and under physiological conditions, including
phosphorylation, mono- and poly-ubiquitination at multiple lysine
residues, as well as truncations and nitration,2 suggesting that these
modifications play a role in a-syn aggregation, LB formation.
Increasing evidence also suggests that a-syn PTMs play important
roles in regulating a-syn degradation by the proteasome or auto-
phagy, subcellular localization and physiological functions.2 Thus, a
better understanding of how a-syn PTMs regulate its functions in
health and disease is crucial for understanding the biology of a-syn.
Achieving this goal requires the ability to obtain homogenous
preparations of chemically well-defined a-syn PTMs, which are
typically diﬃcult to obtain using conventional biochemical methods
that often result in heterogeneousmixtures of products.2 This is due
to the fact that the enzymes responsible for many a-syn PTMs are
not yet known, thus making it diﬃcult to achieve selective modifica-
tions and elucidate the relative contribution of each modification or
cross-talk between diﬀerent PTMs.
In order to overcome these limitations, our group has recently
developed semisynthetic approaches based on expressed protein
ligation (EPL3,4) that allow the introduction of single or multiple
PTMs at the N- or C-terminal regions of a-syn, including N-terminal
acetylation, mono-ubiquitination at K65 and K126 and phosphoryla-
tion at S129 and Y1257. Using thesemethods, wewere able to produce
homogenously modified proteins in milligram quantities and eluci-
date the role of each modification in regulating a-syn structure,
membrane binding, aggregation, subcellular localization and/or
degradation. Subsequently, other groups recently used similar strate-
gies to prepare semisynthetic a-syn, for example containing FRET
probes.8 Protein semisynthesis however restricts the introduction of
PTMs or unnatural amino acids to the termini of a protein, making
some of a-syn PTMs located within themiddle of the protein (such as
pS87) diﬃcult to access via semisynthesis. Moreover, a-syn can be
modified at multiple sites at the same time, suggesting cross-
talk between diﬀerent PTMs.9 Investigating such cross-talk requires
methodologies that allow the simultaneous introduction of multiple
modifications in diﬀerent regions of the protein. Total chemical
synthesis of proteins oﬀers unlimited versatility regarding the type,
number, and localization of unnatural aminoacids to be introduced.10
Here, we present the first report of an eﬃcient one-pot total chemical
synthesis of a-syn and demonstrate that synthetic a-syn exhibits
similar biophysical, membrane binding and aggregation properties
to recombinant a-syn obtained from E. coli.
Given that the chemical synthesis of polypeptide chains of
40–60 residues are typically feasible by Fmoc-based SPPS in sufficient
yields, our initial fragment design for the total synthesis of a-syn was
based on dividing the protein into four segments, a-syn(1–29)SR,
Thz-a-syn(31–68)SR, Thz-a-syn(70–106)SR, and a-syn(A107C-140)OH,
of sequence length in the range of 29–38 residues (Fig. 1A and Fig. S1,
ESI†). Ligation sites were chosen at Ala residues which could be
temporarily mutated to Cys for the native chemical ligation (NCL)11
reaction and readily reverted back to the native Ala via desulfurization
methods.12 N-terminal Cys residues of central fragments were intro-
duced as thiazolidine-(Thz) protected forms, which can be converted
back to free Cys with methoxylamine at acidic pH.13 The syntheses of
the thioester fragments were performed using the N-acylurea
approach.14,15 In order to increase the stability, Nbz groups were
replaced by alkyl thioesters using sodium 2-mercaptoethanesulfonate
(MESNa) before purification. The preparation of the fragments Thz-a-
syn(31–68)SR and Thz-a-syn(70–106)SR was very challenging, with
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initial unacceptably low yields. However, when two Lys-Thr pseudo-
proline dipeptide residues were incorporated at positions 43–44
and 58–59 and the more efficient HATU coupling agent was used
for the coupling of N-terminal residues 30–44, the fragment Thz-a-
syn(31–68)SR was obtained in a reasonable 10% yield. However, the
overall very low yield of Thz-a-syn(70–106)SR could not be improved.
This is not surprising, given that the 70–106 fragment encompassing
the highly hydrophobic and aggregation-prone 61–95 region, also
known as the NAC region,16 which plays a critical role in the initiation
of a-syn aggregation and amyloid formation.
Numerous studies have shown that the highly acidic and
proline-rich disordered C-terminal (96–140) domain enhances the
solubility and thermostability of the full-length protein.17 Dele-
tion of this domain or the last 20 a.a. accelerates a-syn aggrega-
tion.18 Given that the C-terminal fragment a-syn(A107C-140)
posed the least synthetic difficulties, we sought to take advantage
of the increased solubility of this domain in the synthesis of a
longer fragment (69–140) that encompasses the NAC region
during SPPS. Indeed, this strategy was very successful and the
synthesis of the 72 residue fragment a-syn(A69C-140) was
achieved with a very good 14% yield (Fig. S3, ESI†). The optimal
conditions for generating this fragment included HATU as a
coupling agent from residues 85 to 69 and a Lys-Thr pseudopro-
line dipeptide at positions 81–82 (Fig. S1 and Table S1, ESI†).
These results demonstrate the utility of unstructured portions of
the native a-syn sequence, which can fortuitously enhance access
to more synthetically challenging regions.
With suﬃcient quantities of purified fragments 1 a-syn(A69C-140),
2 Thz-a-syn(31–68)SR, and 3 a-syn(1–29)SR in hand, we were prepared
to assemble full-length wild-type a-syn by applying two sequential
NCL steps in a one-pot synthesis scheme, which takes advantage of
the pH-dependence of NCL (pH 7–8) and the conversion of the Thz to
Cys (pH 3.8–4) to orchestrate the desired transformations by con-
trolled pH switching (Fig. 1B and Fig. S2, ESI†). The first ligation
between peptides 1 and 2was carried out at pH 7.5 in 6.0 MGdnHCl,
0.2 M sodium phosphate in the presence of 30 mM tris(2-carbox-
yethyl)phosphine (TCEP) and 50 mM 4-mercaptophenylacetic acid
(MPAA) as a NCL catalyst.19 The formation of the ligated product 4
Thz-a-syn(31–140) A69C was complete within 3 h, as demonstrated by
the appearance of a new peak using RP-UHPLC (Fig. 1B) with the
observed mass of 11561 Da (calc.: 11561 Da, M + H+) determined
using MALDI-TOF MS (Fig. S4B, ESI†). Treatment with methoxyl-
amine at pH 4.0 unmasked the N-terminal cysteine, generating
the intermediate product 5 a-syn(30–140) A30C A69C within 2.5 h
(Fig. S4C, ESI†). A second ligation step was performed by raising the
pH to 7.5 and adding the N-terminal a-syn fragment 3 a-syn(1–29)SR,
which afforded the full-length protein 6 a-syn(1–140) A30C A69C
within 2–3 h (Fig. 1C). Note that the N-terminus of peptide 3 was
not Na-acetylated since we previously showed this modification to
have no major impact on the native oligomeric state of a-syn.20
Fig. 1 One-pot synthesis of wt a-syn. (A) Schematic depiction of the a-syn sequence and the peptides chosen for the three-fragment synthetic strategy. (B) Scheme
depicting the successive reactions to obtain full-length wt a-syn using the three-fragment strategy. (C) RP-UHPLC (left panel) and SDS-PAGE (right panel) analyses of
the ligation between a-syn(A69C–140) and Thz-a-syn(31–68)SR. (D) RP-UHPLC (left panel) and SDS-PAGE (right panel) analyses of the second ligation reaction,
between a-syn(30–140) A30C A69C and a-syn(1–29)SR. In the SDS-PAGE, lane ‘C’ denotes recombinant full-length a-syn control. (E) Purity analyses of the final
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MALDI-TOF MS analysis confirmed the identity of 6 with an
observed mass of 14 525 Da (calc.: 14 525 Da, M + H+, Fig. S4E,
ESI†) Excess MPAA from the ligation was then removed by
desalting with a PD-10 column.
Free-radical desulfurization21 was then applied (see ESI†). The
conversion of both cysteines at positions 30 and 69 occurred within
1 h of reaction as seen using MALDI-TOF MS with an observed
mass of 14464 Da (calc.: 14461 Da, M + H+). The protein was then
purified on a C8 semipreparative column and recovered with >95%
purity with a 21% yield (0.21 mmol, 3 mg, Fig. 1D). Because a-syn is
a natively unfolded protein,22 it does not require a refolding step
after ligation and desulfurization.
We then sought to verify that the synthetic protein behaves
similarly to the most commonly used form of a-syn, recombinant
a-syn produced in E. coli (not N-terminally acetylated) and purified
using the same procedure. Freshly-dissolved synthetic wt a-syn was
indistinguishable from the recombinant protein using circular
dichroism spectroscopy, showing that both proteins exist predomi-
nantly in random coil conformations (Fig. 2A), and showed similar
aﬃnities for 100 nm diameter large unilamellar vesicles composed
of phosphatidylglycerol (POPG) (Fig. 2A). Multi-angle light
scattering confirmed that both freshly-prepared proteins behaved
as monomers, as expected (Fig. 2B). Fibrillization studies using
ThT fluorescence (Fig. 2C) did not reveal a significant diﬀerence
between the end-point amyloid formation propensity of recombi-
nant and synthetic wt a-syn. Furthermore, the loss of soluble
protein as a result of aggregation was similar between both
forms as assessed by SDS-PAGE analysis of supernatants after
high-speed centrifugation (Fig. 2D), although synthetic a-syn
seemed to aggregate slightly slower than the recombinant
protein. Transmission electron microscopy (TEM) showed that
recombinant and synthetic wt a-syn form similar fibrillar
structures upon aggregation (Fig. 2E).
In conclusion, we have described a strategy enabling the one-pot
total chemical synthesis of a-syn using three peptide fragments.
This method will enable the preparation ofmodified forms of a-syn
(such as pS87) that have not been accessible so far using
semisynthetic methods because of their location in the center
of the protein; as well as combinations of diﬀerent PTMs in
order to explore the possibility of cross-talk between them.
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Fig. 2 Biophysical and biochemical characterization of synthetic wt a-syn in
comparison with the recombinant protein. (A) Circular dichroism spectra of
recombinant and synthetic wt a-syn. (B) Size-exclusion chromatography/multi-
angle light scattering analysis. The left ordinate axis shows the absorbance
profiles (275 nm); the right ordinate axis shows the calculated molecular weights.
(C) ThT fluorescence analysis. (D) SDS-PAGE analysis of the soluble protein
content during the aggregation of recombinant and synthetic wt a-syn. The
lower panel shows quantification (three independent experiments) of the SDS-
PAGE gels. A representative gel is shown in the upper panel. (E) TEM micrographs
taken after 5 days of aggregation. Scale bars: 100 nm.
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